Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature
- PMID: 19154416
- PMCID: PMC11159285
- DOI: 10.1111/j.1349-7006.2008.01072.x
Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature
Abstract
Heat shock protein (Hsp) 90 is a key regulator of a variety of oncogene products and cell-signaling molecules, and the therapeutic benefit of its inhibition in combination with radiation or chemotherapy has been investigated. In addition, hyperthermia has been used for many years to treat various malignant tumors. We previously described a system in which hyperthermia was induced using thermosensitive ferromagnetic particles (FMP) with a Curie temperature (Tc = 43 degrees C) low enough to mediate automatic temperature control, and demonstrated its antitumor effect in a mouse melanoma model. In the present study, we examined the antitumor effects of combining a Hsp90 inhibitor (geldanamycin; GA) with FMP-mediated hyperthermia. In cultured B16 melanoma cells, GA exerted an antitumor effect by increasing the cells' susceptibility to hyperthermia and reducing expression of Akt. In an in vivo study, melanoma cells were subcutaneously injected into the backs of C57BL/6 mice. FMP were then injected into the resultant tumors, and the mice were divided into four groups: group I, no treatment (control); group II, one hyperthermia treatment; group III, GA alone; and group IV, GA with hyperthermia. When exposed to a magnetic field, the temperature of tissues containing FMP increased and stabilized at the Tc. In group IV, complete regression of tumors was observed in five of nine mice (56%), whereas no tumor regression was seen in groups I-III. Our findings suggest that inhibition of Hsp90 with hyperthermia increases its antitumor effect. Thus, the combination of FMP-mediated, self-regulating hyperthermia with Hsp90 inhibition has important implications for the treatment of cancer.
Figures

















Similar articles
-
Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature.Int J Clin Oncol. 2014 Aug;19(4):722-30. doi: 10.1007/s10147-013-0606-x. Epub 2013 Aug 15. Int J Clin Oncol. 2014. PMID: 23949287
-
Self-regulating hyperthermia induced using thermosensitive ferromagnetic material with a low Curie temperature.Cancer Sci. 2008 Apr;99(4):805-9. doi: 10.1111/j.1349-7006.2008.00726.x. Epub 2008 Feb 21. Cancer Sci. 2008. PMID: 18294293 Free PMC article.
-
Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates.Int J Hyperthermia. 2014 Dec;30(8):550-64. doi: 10.3109/02656736.2014.974694. Epub 2014 Nov 18. Int J Hyperthermia. 2014. PMID: 25403416
-
Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin.J Control Release. 2007 Sep 11;122(1):16-23. doi: 10.1016/j.jconrel.2007.06.005. Epub 2007 Jun 14. J Control Release. 2007. PMID: 17651857
-
The Curie temperature: a key playmaker in self-regulated temperature hyperthermia.J Mater Chem B. 2024 Jan 3;12(2):286-331. doi: 10.1039/d3tb01437a. J Mater Chem B. 2024. PMID: 37955235 Review.
Cited by
-
Inhibitors of HSP90 in melanoma.Apoptosis. 2020 Feb;25(1-2):12-28. doi: 10.1007/s10495-019-01577-1. Apoptosis. 2020. PMID: 31659567 Free PMC article. Review.
-
A Bioinformatic Approach for the Identification of Molecular Determinants of Resistance/Sensitivity to Cancer Thermotherapy.Oxid Med Cell Longev. 2019 Nov 11;2019:4606219. doi: 10.1155/2019/4606219. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31814876 Free PMC article.
-
Thermal potentiation of chemotherapy by magnetic nanoparticles.Nanomedicine (Lond). 2013 Oct;8(10):1689-707. doi: 10.2217/nnm.13.146. Nanomedicine (Lond). 2013. PMID: 24074390 Free PMC article. Review.
-
Biologically Targeted Magnetic Hyperthermia: Potential and Limitations.Front Pharmacol. 2018 Aug 2;9:831. doi: 10.3389/fphar.2018.00831. eCollection 2018. Front Pharmacol. 2018. PMID: 30116191 Free PMC article. Review.
-
An in vitro and in vivo investigation of the biological behavior of a ferrimagnetic cement for highly focalized thermotherapy.J Mater Sci Mater Med. 2010 Aug;21(8):2413-23. doi: 10.1007/s10856-010-4093-6. Epub 2010 Jun 15. J Mater Sci Mater Med. 2010. PMID: 20549312
References
-
- Cavaliere R, Ciocatto EC, Giovanella BC et al . Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20: 1351–81. - PubMed
-
- Overgaard K, Overgaard J. Investigations on the possibility of a thermic tumour therapy. I. Short‐wave treatment of a transplanted isologous mouse mammary carcinoma. Eur J Cancer 1972; 8: 65–78. - PubMed
-
- Lefor AT, Makohon S, Ackerman NB. The effects of hyperthermia on vascular permeability in experimental liver metastasis. J Surg Oncol 1985; 28: 297–300. - PubMed
-
- Hiraoka M, Jo S, Akuta K, Nishimura Y, Takahashi M, Abe M. Radiofrequency capacitive hyperthermia for deep‐seated tumors. I. Studies on thermometry. Cancer 1987; 60: 121–7. - PubMed
-
- Van Der Zee J. Heating the patient: a promising approach? Ann Oncol 2002; 13: 1173–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical